Novel insights in FGFR1 regulation: Lessons from Kallmann syndrome

Trends in Endocrinology and Metabolism

Volumn 21, Issue 6, 2010, Pages 385-393

  Hu, Youli ^a   Bouloux, Pierre Marc ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANOSMIN 1; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GONADORELIN; MEMBRANE PROTEIN; PHOSPHOLIPASE C; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; SULFOTRANSFERASE; UNCLASSIFIED DRUG;

BINDING AFFINITY; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; DIMERIZATION; GENE DISRUPTION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; KALLMANN SYNDROME; LOSS OF FUNCTION MUTATION; MODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN GLYCOSYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE;

HUMANS; INHERITANCE PATTERNS; KALLMANN SYNDROME; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; SIGNAL TRANSDUCTION;

EID: 77953358407     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2010.01.004     Document Type: Review

References (73)

1. Dvorak P., et al. Fibroblast growth factor signaling in embryonic and cancer stem cells. FEBS Lett. 2006, 580:2869-2874.
2. Eswarakumar V.P., et al. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005, 16:139-149.
3. Detillieux K.A., et al. Biological activities of fibroblast growth factor-2 in the adult myocardium. Cardiovasc. Res. 2003, 57:8-19.
4. Ornitz D.M., Marie P.J. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev. 2002, 16:1446-1465.
5. Ornitz D.M. FGF signaling in the developing endochondral skeleton. Cytokine Growth Factor Rev. 2005, 16:205-213.
6. Freeman K.W., et al. Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation. Cancer Res. 2003, 63:6237-6243.
7. Mohammadi M., et al. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 2005, 16:107-137.
8. Doherty P., Walsh F.S. CAM-FGF receptor interactions: a model for axonal growth. Mol. Cell Neurosci. 1996, 8:99-111.
9. Duchesne L., et al. N-glycosylation of fibroblast growth factor receptor 1 regulates ligand and heparan sulfate co-receptor binding. J. Biol. Chem. 2006, 281:27178-27189.
10. Kirschbaum K., et al. Analysis of non-canonical fibroblast growth factor receptor 1 (FGFR1) interaction reveals regulatory and activating domains of neurofascin. J. Biol. Chem. 2009, 284:28533-28542.
11. Kiselyov V.V., et al. Structural biology of NCAM homophilic binding and activation of FGFR. J. Neurochem. 2005, 94:1169-1179.
12. Kim S.H., et al. Diversity in fibroblast growth factor receptor 1 regulation: learning from the investigation of Kallmann syndrome. J. Neuroendocrinol. 2008, 20:141-163.
13. Olsen S.K., et al. Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proc. Natl. Acad. Sci. U. S. A 2004, 101:935-940.
14. Dode C., et al. Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat. Genet. 2003, 33:463-465.
15. Pitteloud N., et al. Mutations in fibroblast growth factor receptor 1 cause Kallmann syndrome with a wide spectrum of reproductive phenotypes. Mol. Cell Endocrinol. 2006, 254-255:60-69.
16. Pitteloud N., et al. Mutations in fibroblast growth factor receptor 1 cause both Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proc. Natl. Acad. Sci. U. S. A 2006, 103:6281-6286.
17. Hebert J.M., et al. FGF signaling through FGFR1 is required for olfactory bulb morphogenesis. Development 2003, 130:1101-1111.
18. Tsai P.S., et al. Targeted expression of a dominant-negative fibroblast growth factor (FGF) receptor in gonadotropin-releasing hormone (GnRH) neurons reduces FGF responsiveness and the size of GnRH neuronal population. Mol. Endocrinol. 2005, 19:225-236.
19. Chung W.C., et al. Fibroblast growth factor 8 signaling through fibroblast growth factor receptor 1 is required for the emergence of gonadotropin-releasing hormone neurons. Endocrinology 2008, 149:4997-5003.
20. Dode C., et al. Novel FGFR1 sequence variants in Kallmann syndrome, and genetic evidence that the FGFR1c isoform is required in olfactory bulb and palate morphogenesis. Hum. Mutat. 2007, 28:97-98.
21. Dode C., Hardelin J.P. Kallmann syndrome. Eur. J. Hum. Genet. 2009, 17:139-146.
22. Trarbach E.B., et al. Novel fibroblast growth factor receptor 1 mutations in patients with congenital hypogonadotropic hypogonadism with and without anosmia. J. Clin. Endocrinol. Metab 2006, 91:4006-4012.
23. Miki T., et al. Expression cDNA cloning of the KGF receptor by creation of a transforming autocrine loop. Science 1991, 251:72-75.
24. Pitteloud N., et al. Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. J. Clin. Invest 2007, 117:457-463.
25. Falardeau J., et al. Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice. J. Clin. Invest 2008, 118:2822-2831.
26. Meyers E.N., et al. An Fgf8 mutant allelic series generated by Cre- and Flp-mediated recombination. Nat. Genet. 1998, 18:136-141.
27. Zheng W., et al. Fibroblast growth factor 2 is required for maintaining the neural stem cell pool in the mouse brain subventricular zone. Dev. Neurosci. 2004, 26:181-196.
28. Harmer N.J. Insights into the role of heparan sulphate in fibroblast growth factor signalling. Biochem. Soc. Trans. 2006, 34:442-445.
29. Guimond S.E., Turnbull J.E. Fibroblast growth factor receptor signalling is dictated by specific heparan sulphate saccharides. Curr. Biol. 1999, 9:1343-1346.
30. Ostrovsky O., et al. Differential effects of heparin saccharides on the formation of specific fibroblast growth factor (FGF) and FGF receptor complexes. J. Biol. Chem. 2002, 277:2444-2453.
31. Grobe K., et al. Cerebral hypoplasia and craniofacial defects in mice lacking heparan sulfate Ndst1 gene function. Development 2005, 132:3777-3786.
32. Franco B., et al. A gene deleted in Kallmann's syndrome shares homology with neural cell adhesion and axonal path-finding molecules. Nature 1991, 353:529-536.
33. Legouis R., et al. The candidate gene for the X-linked Kallmann syndrome encodes a protein related to adhesion molecules. Cell 1991, 67:423-435.
34. Hu Y., et al. Novel mechanisms of fibroblast growth factor receptor 1 regulation by extracellular matrix protein anosmin-1. J. Biol. Chem. 2009, 284:29905-29920.
35. Raivio T., et al. Impaired fibroblast growth factor receptor 1 signaling as a cause of normosmic idiopathic hypogonadotropic hypogonadism. J. Clin. Endocrinol. Metab 2009, 94:4380-4390.
36. Robertson A., et al. Molecular modelling and experimental studies of mutation and cell-adhesion sites in the fibronectin type III and whey acidic protein domains of human anosmin-1. Biochem. J. 2001, 357:647-659.
37. Gonzalez-Martinez D., et al. Anosmin-1 modulates fibroblast growth factor receptor 1 signaling in human gonadotropin-releasing hormone olfactory neuroblasts through a heparan sulfate-dependent mechanism. J. Neurosci. 2004, 24:10384-10392.
38. Oliveira L.M., et al. The importance of autosomal genes in Kallmann syndrome: genotype-phenotype correlations and neuroendocrine characteristics. J. Clin. Endocrinol. Metab 2001, 86:1532-1538.
39. Schlessinger J., et al. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol. Cell 2000, 6:743-750.
40. Pellegrini L., et al. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 2000, 407:1029-1034.
41. Goodger S.J., et al. Evidence that heparin saccharides promote FGF2 mitogenesis through two distinct mechanisms. J. Biol. Chem. 2008, 283:13001-13008.
42. Harmer N.J., et al. Towards a resolution of the stoichiometry of the fibroblast growth factor (FGF)-FGF receptor-heparin complex. J. Mol. Biol. 2004, 339:821-834.
43. Hu Y., et al. Cross-talk of anosmin-1, the protein implicated in X-linked Kallmann's syndrome, with heparan sulphate and urokinase-type plasminogen activator. Biochem. J. 2004, 384:495-505.
44. Soussi-Yanicostas N., et al. Anosmin-1 underlying the X chromosome-linked Kallmann syndrome is an adhesion molecule that can modulate neurite growth in a cell-type specific manner. J. Cell Sci. 1998, 111(Pt 19):2953-2965.
45. Bottcher R.T., et al. The transmembrane protein XFLRT3 forms a complex with FGF receptors and promotes FGF signalling. Nat. Cell Biol. 2004, 6:38-44.
46. Tsang M., et al. Identification of Sef, a novel modulator of FGF signalling. Nat. Cell Biol. 2002, 4:165-169.
47. Doherty P., et al. CAMs and axonal growth: a critical evaluation of the role of calcium and the MAPK cascade. Mol. Cell Neurosci. 2000, 16:283-295.
48. Zhang W., et al. Antiangiogenic antithrombin blocks the heparan sulfate-dependent binding of proangiogenic growth factors to their endothelial cell receptors: evidence for differential binding of antiangiogenic and anticoagulant forms of antithrombin to proangiogenic heparan sulfate domains. J. Biol. Chem. 2006, 281:37302-37310.
49. Schwanzel-Fukuda M., Pfaff D.W. Origin of luteinizing hormone-releasing hormone neurons. Nature 1989, 338:161-164.
50. Soussi-Yanicostas N., et al. Anosmin-1, defective in the X-linked form of Kallmann syndrome, promotes axonal branch formation from olfactory bulb output neurons. Cell 2002, 109:217-228.
51. Yanicostas C., et al. Anosmin-1a is required for fasciculation and terminal targeting of olfactory sensory neuron axons in the zebrafish olfactory system. Mol. Cell Endocrinol. 2009, 312:53-60.
52. Cariboni A., et al. The product of X-linked Kallmann's syndrome gene (KAL1) affects the migratory activity of gonadotropin-releasing hormone (GnRH)-producing neurons. Hum. Mol. Genet. 2004, 13:2781-2791.
53. Bribian A., et al. Anosmin-1 modulates the FGF-2-dependent migration of oligodendrocyte precursors in the developing optic nerve. Mol. Cell Neurosci. 2006, 33:2-14.
54. Dode C., et al. Kallmann syndrome: mutations in the genes encoding prokineticin-2 and prokineticin receptor-2. PLoS. Genet. 2006, 2:e175.
55. Pitteloud N., et al. Loss-of-function mutation in the prokineticin 2 gene causes Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proc. Natl. Acad. Sci. U. S. A 2007, 104:17447-17452.
56. Ngan E.S., Tam P.K. Prokineticin-signaling pathway. Int. J. Biochem. Cell Biol. 2008, 40:1679-1684.
57. LeCouter J., et al. The endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis: Localization of Bv8 receptors to endothelial cells. Proc. Natl. Acad. Sci. U. S. A 2003, 100:2685-2690.
58. Yamazaki Y., Morita T. Molecular and functional diversity of vascular endothelial growth factors. Mol. Divers. 2006, 10:515-527.
59. Delcourt N., et al. GPCR-jacking: from a new route in RTK signalling to a new concept in GPCR activation. Trends Pharmacol. Sci. 2007, 28:602-607.
60. Wetzker R., Bohmer F.D. Transactivation joins multiple tracks to the ERK/MAPK cascade. Nat. Rev. Mol. Cell Biol. 2003, 4:651-657.
61. Rauch B.H., et al. Thrombin- and factor Xa-induced DNA synthesis is mediated by transactivation of fibroblast growth factor receptor-1 in human vascular smooth muscle cells. Circ. Res. 2004, 94:340-345.
62. Ayari B., Soussi-Yanicostas N. FGFR1 and anosmin-1 underlying genetically distinct forms of Kallmann syndrome are co-expressed and interact in olfactory bulbs. Dev. Genes Evol. 2007, 217:169-175.
63. Puverel S., et al. Prokineticin receptor 2 expression identifies migrating neuroblasts and their subventricular zone transient-amplifying progenitors in adult mice. J. Comp Neurol. 2009, 512:232-242.
64. Bulow H.E., Hobert O. Differential sulfations and epimerization define heparan sulfate specificity in nervous system development. Neuron 2004, 41:723-736.
65. Whitlock K.E., et al. A role for foxd3 and sox10 in the differentiation of gonadotropin-releasing hormone (GnRH) cells in the zebrafish Danio rerio. Development 2005, 132:5491-5502.
66. Hardelin J.P., et al. Heterogeneity in the mutations responsible for X chromosome-linked Kallmann syndrome. Hum. Mol. Genet. 1993, 2:373-377.
67. Quinton R., et al. The neuroradiology of Kallmann's syndrome: a genotypic and phenotypic analysis. J. Clin. Endocrinol. Metab 1996, 81:3010-3017.
68. Quinton R., et al. Idiopathic gonadotrophin deficiency: genetic questions addressed through phenotypic characterization. Clin. Endocrinol. (Oxf) 2001, 55:163-174.
69. Albuisson J., et al. Kallmann syndrome: 14 novel mutations in KAL1 and FGFR1 (KAL2). Hum. Mutat. 2005, 25:98-99.
70. Hu Y., et al. Extended and flexible domain solution structure of the extracellular matrix protein anosmin-1 by X-ray scattering, analytical ultracentrifugation and constrained modelling. J. Mol. Biol. 2005, 350:553-570.
71. Miura K., et al. Characterization of the human nasal embryonic LHRH factor gene, NELF, and a mutation screening among 65 patients with idiopathic hypogonadotropic hypogonadism (IHH). J. Hum. Genet. 2004, 49:265-268.
72. Kim H.G., et al. Mutations in CHD7, encoding a chromatin-remodeling protein, cause idiopathic hypogonadotropic hypogonadism and Kallmann syndrome. Am. J. Hum. Genet. 2008, 83:511-519.
73. Semple R.K., Kemal T.A. The recent genetics of hypogonadotrophic hypogonadism - novel insights and new questions. Clin. Endocrinol. (Oxf) 2009, 10.1111/j.1365-2265.2009.03687.x.